Global Lung Disease Therapeutics Industry

2023-2029 Global Lung Disease Therapeutics Industry Research & Trends Analysis Report

Global Lung Disease Therapeutics Industry

2023-2029 Global Lung Disease Therapeutics Industry Research & Trends Analysis Report


Analysis of the Lung Disease Therapeutics Market reveals emerging trends, consumer adoption rates, and competitive strategies among leading manufacturers worldwide.

Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

According to the latest research analysis,the global market for Lung Disease Therapeutics should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

China Lung Disease Therapeutics market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

The United States Lung Disease Therapeutics market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

In terms of disease type, Asthma segment holds a share about % in 2022 and will reach % in 2029; while in terms of distribution channel, Hospital Pharmacies has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.


The global key manufacturers of Lung Disease Therapeutics include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals and Cipla, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for Lung Disease Therapeutics.
Data-Driven Insights: Highlights from Our Report

(1) Global Lung Disease Therapeutics market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.

(2) Global Lung Disease Therapeutics market competitive situation, revenue and market share, from 2018 to 2022.

(3) China Lung Disease Therapeutics market competitive situation, revenue and market share, from 2018 to 2022.

(4) Global Lung Disease Therapeutics segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Lung Disease Therapeutics segment by type and by application and regional segment by type and by application.

(6) Lung Disease Therapeutics industry supply chain, upstream, midstream and downstream analysis.


Breaking Down Market Segments by Region: A Deep Dive Analysis

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by disease type, covers

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Lung Cancer

Other Lung Diseases

Market segment by distribution channel, can be divided into

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies


Understanding Market Segments by Key Players: Insights and Opportunities

GSK

AstraZeneca

Boehringer Ingelheim

Novartis

Mylan

Vertex Pharmaceuticals

F. Hoffman La Roche

Teva Pharmaceuticals

Cipla

Fibrogen

Liminal Biosciences

PharmAkea Therapeutics

IQVIA

1 Market Overview

1.1 Product Overview and Scope of Lung Disease Therapeutics

1.2 Global Lung Disease Therapeutics Market Size and Forecast

1.3 China Lung Disease Therapeutics Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Lung Disease Therapeutics Share in Global Market, 2018-2029

1.4.2 Lung Disease Therapeutics Market Size: China VS Global, 2018-2029

1.5 Lung Disease Therapeutics Market Dynamics

1.5.1 Lung Disease Therapeutics Market Drivers

1.5.2 Lung Disease Therapeutics Market Restraints

1.5.3 Lung Disease Therapeutics Industry Trends

1.5.4 Lung Disease Therapeutics Industry Policy

2 Global Competitive Situation by Company

2.1 Global Lung Disease Therapeutics Revenue by Company (2018-2023)

2.2 Global Lung Disease Therapeutics Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Lung Disease Therapeutics Concentration Ratio

2.4 Global Lung Disease Therapeutics Mergers & Acquisitions, Expansion Plans

2.5 Global Lung Disease Therapeutics Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Lung Disease Therapeutics Revenue by Company (2018-2023)

3.2 China Lung Disease Therapeutics Lung Disease Therapeutics Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Lung Disease Therapeutics, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)

4 Industry Chain Analysis

4.1 Lung Disease Therapeutics Industry Chain

4.2 Lung Disease Therapeutics Upstream Analysis

4.3 Lung Disease Therapeutics Midstream Analysis

4.4 Lung Disease Therapeutics Downstream Analysis

5 Sights by Disease Type

5.1 Lung Disease Therapeutics Classification

5.1.1 Asthma

5.1.2 Chronic Obstructive Pulmonary Disease (COPD)

5.1.3 Lung Cancer

5.1.4 Other Lung Diseases

5.2 By Disease Type, Global Lung Disease Therapeutics Market Size & CAGR, 2018 VS 2022 VS 2029

5.3 By Disease Type, Global Lung Disease Therapeutics Revenue, 2018-2029

6 Sights by Distribution Channel

6.1 Lung Disease Therapeutics Segment by Distribution Channel

6.1.1 Hospital Pharmacies

6.1.2 Retail Pharmacies

6.1.3 Online Pharmacies

6.2 By Application, Global Lung Disease Therapeutics Market Size & CAGR, 2018 VS 2022 VS 2029

6.3 By Application, Global Lung Disease Therapeutics Revenue, 2018-2029

7 Sales Sights by Region

7.1 By Region, Global Lung Disease Therapeutics Market Size, 2018 VS 2022 VS 2029

7.2 By Region, Global Lung Disease Therapeutics Market Size, 2018-2029

7.3 North America

7.3.1 North America Lung Disease Therapeutics Market Size & Forecasts, 2018-2029

7.3.2 By Country, North America Lung Disease Therapeutics Market Size Market Share

7.4 Europe

7.4.1 Europe Lung Disease Therapeutics Market Size & Forecasts, 2018-2029

7.4.2 By Country, Europe Lung Disease Therapeutics Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Lung Disease Therapeutics Market Size & Forecasts, 2018-2029

7.5.2 By Country/Region, Asia Pacific Lung Disease Therapeutics Market Size Market Share

7.6 South America

7.6.1 South America Lung Disease Therapeutics Market Size & Forecasts, 2018-2029

7.6.2 By Country, South America Lung Disease Therapeutics Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Lung Disease Therapeutics Market Size & CAGR，2018 VS 2022 VS 2029

8.2 By Country, Global Lung Disease Therapeutics Market Size, 2018-2029

8.3 U.S.

8.3.1 U.S. Lung Disease Therapeutics Market Size, 2018-2029

8.3.2 By Company, U.S. Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.3.3 By Disease Type, U.S. Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.3.4 By Distribution Channel, U.S. Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Lung Disease Therapeutics Market Size, 2018-2029

8.4.2 By Company, Europe Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.4.3 By Disease Type, Europe Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.4.4 By Distribution Channel, Europe Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.5 China

8.5.1 China Lung Disease Therapeutics Market Size, 2018-2029

8.5.2 By Company, China Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.5.3 By Disease Type, China Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.5.4 By Distribution Channel, China Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Lung Disease Therapeutics Market Size, 2018-2029

8.6.2 By Company, Japan Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.6.3 By Disease Type, Japan Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.6.4 By Distribution Channel, Japan Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Lung Disease Therapeutics Market Size, 2018-2029

8.7.2 By Company, South Korea Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.7.3 By Disease Type, South Korea Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.7.4 By Distribution Channel, South Korea Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Lung Disease Therapeutics Market Size, 2018-2029

8.8.2 By Company, Southeast Asia Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.8.3 By Disease Type, Southeast Asia Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.8.4 By Distribution Channel, Southeast Asia Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.9 India

8.9.1 India Lung Disease Therapeutics Market Size, 2018-2029

8.9.2 By Company, India Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.9.3 By Disease Type, India Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.9.4 By Distribution Channel, India Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.10 Middle East & Asia

8.10.1 Middle East & Asia Lung Disease Therapeutics Market Size, 2018-2029

8.10.2 By Company, Middle East & Asia Lung Disease Therapeutics Revenue Market Share, 2018-2023

8.10.3 By Disease Type, Middle East & Asia Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

8.10.4 By Distribution Channel, Middle East & Asia Lung Disease Therapeutics Revenue Market Share, 2022 VS 2029

9 Global Manufacturers Profile

9.1 GSK

9.1.1 GSK Company Information, Head Office, Market Area and Industry Position

9.1.2 GSK Company Profile and Main Business

9.1.3 GSK Lung Disease Therapeutics Models, Specifications and Application

9.1.4 GSK Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.1.5 GSK Recent Developments

9.2 AstraZeneca

9.2.1 AstraZeneca Company Information, Head Office, Market Area and Industry Position

9.2.2 AstraZeneca Company Profile and Main Business

9.2.3 AstraZeneca Lung Disease Therapeutics Models, Specifications and Application

9.2.4 AstraZeneca Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.2.5 AstraZeneca Recent Developments

9.3 Boehringer Ingelheim

9.3.1 Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position

9.3.2 Boehringer Ingelheim Company Profile and Main Business

9.3.3 Boehringer Ingelheim Lung Disease Therapeutics Models, Specifications and Application

9.3.4 Boehringer Ingelheim Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.3.5 Boehringer Ingelheim Recent Developments

9.4 Novartis

9.4.1 Novartis Company Information, Head Office, Market Area and Industry Position

9.4.2 Novartis Company Profile and Main Business

9.4.3 Novartis Lung Disease Therapeutics Models, Specifications and Application

9.4.4 Novartis Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.4.5 Novartis Recent Developments

9.5 Mylan

9.5.1 Mylan Company Information, Head Office, Market Area and Industry Position

9.5.2 Mylan Company Profile and Main Business

9.5.3 Mylan Lung Disease Therapeutics Models, Specifications and Application

9.5.4 Mylan Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.5.5 Mylan Recent Developments

9.6 Vertex Pharmaceuticals

9.6.1 Vertex Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

9.6.2 Vertex Pharmaceuticals Company Profile and Main Business

9.6.3 Vertex Pharmaceuticals Lung Disease Therapeutics Models, Specifications and Application

9.6.4 Vertex Pharmaceuticals Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.6.5 Vertex Pharmaceuticals Recent Developments

9.7 F. Hoffman La Roche

9.7.1 F. Hoffman La Roche Company Information, Head Office, Market Area and Industry Position

9.7.2 F. Hoffman La Roche Company Profile and Main Business

9.7.3 F. Hoffman La Roche Lung Disease Therapeutics Models, Specifications and Application

9.7.4 F. Hoffman La Roche Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.7.5 F. Hoffman La Roche Recent Developments

9.8 Teva Pharmaceuticals

9.8.1 Teva Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

9.8.2 Teva Pharmaceuticals Company Profile and Main Business

9.8.3 Teva Pharmaceuticals Lung Disease Therapeutics Models, Specifications and Application

9.8.4 Teva Pharmaceuticals Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.8.5 Teva Pharmaceuticals Recent Developments

9.9 Cipla

9.9.1 Cipla Company Information, Head Office, Market Area and Industry Position

9.9.2 Cipla Company Profile and Main Business

9.9.3 Cipla Lung Disease Therapeutics Models, Specifications and Application

9.9.4 Cipla Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.9.5 Cipla Recent Developments

9.10 Fibrogen

9.10.1 Fibrogen Company Information, Head Office, Market Area and Industry Position

9.10.2 Fibrogen Company Profile and Main Business

9.10.3 Fibrogen Lung Disease Therapeutics Models, Specifications and Application

9.10.4 Fibrogen Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.10.5 Fibrogen Recent Developments

9.11 Liminal Biosciences

9.11.1 Liminal Biosciences Company Information, Head Office, Market Area and Industry Position

9.11.2 Liminal Biosciences Company Profile and Main Business

9.11.3 Liminal Biosciences Lung Disease Therapeutics Models, Specifications and Application

9.11.4 Liminal Biosciences Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.11.5 Liminal Biosciences Recent Developments

9.12 PharmAkea Therapeutics

9.12.1 PharmAkea Therapeutics Company Information, Head Office, Market Area and Industry Position

9.12.2 PharmAkea Therapeutics Company Profile and Main Business

9.12.3 PharmAkea Therapeutics Lung Disease Therapeutics Models, Specifications and Application

9.12.4 PharmAkea Therapeutics Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.12.5 PharmAkea Therapeutics Recent Developments

9.13 IQVIA

9.13.1 IQVIA Company Information, Head Office, Market Area and Industry Position

9.13.2 IQVIA Company Profile and Main Business

9.13.3 IQVIA Lung Disease Therapeutics Models, Specifications and Application

9.13.4 IQVIA Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023

9.13.5 IQVIA Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Lung Disease Therapeutics Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
What is the estimated size & growth rate of the Lung Disease Therapeutics Market?
In recent years, the Lung Disease Therapeutics Market has grown at an incredible rate. From 2025 to 2030, the market is expected to grow at a CAGR of yy%.
What trends may have an impact on the Lung Disease Therapeutics Market's growth?
A handful of disruptive trends, nevertheless, will have a contradictory and significant impact on the development of the Lung Disease Therapeutics Market as well as its distribution among its players
What is the estimated global market value of the Lung Disease Therapeutics Market?
The Lung Disease Therapeutics Market is expected to reach a considerable market valuation.